SCHEMBL13498293

SCHEMBL13498293

CCNCCC(C)Cc1c(-c2ccc3c(c2)CCNC3=O)ccc2cnc(Nc3ccc(S(N)(=O)=O)cc3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 11/20 0.41
CDK4 P11802 4/20 0.37
CDK6 Q00534 4/20 0.37
CCND1 P24385 2/20 0.37
CCND3 P30281 2/20 0.37
PIM1 P11309 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
CCNA2 P20248 4/20 0.37
CDK2 P24941 4/20 0.37
CCNA1 P78396 1/20 0.37
CCNT1 O60563 1/20 0.36
CDK7 P50613 1/20 0.36
CDK9 P50750 1/20 0.36
CCNH P51946 1/20 0.36
MNAT1 P51948 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA9 Q16790 1/20 0.36
DKK1 O94907 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633494 0.79 PIM1 (0.54) IKBKBPIM1PIM2CA1CA2
SCHEMBL1633110 0.78 IKBKB (0.47) IKBKBCDK4CDK6CCND1CCND3
SCHEMBL1632840 0.77 IKBKB (0.48) IKBKBCDK4CDK6CCND1CCND3
SCHEMBL1633082 0.74 IKBKB (0.45) IKBKBCDK4CDK6CCND1CCND3
SCHEMBL1474734 0.66 AURKA (0.52) IKBKBCDK4CDK6CCNA2CDK2
SCHEMBL1634935 0.64 STK17A (0.50) CDK4CDK6CCND1CCND3GSK3B
SCHEMBL13498354 0.64 MAPK10 (0.49) IKBKBCDK4CCND1CCNA2CDK2
SCHEMBL12495785 0.62 PARP10 (0.47) GSK3B
SCHEMBL12077346 0.61 MAPK1 (0.51)
SCHEMBL13498245 0.61 CDK2 (0.48) IKBKBCDK4CCND1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 IKBKB 980/4885CDK4 24/4885CDK6 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.